Article
An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation.
Blood cells, molecules & diseases - 1 Dec 2015
Maia Raquel Ciuvalschi, Bonamino Martin Hernan, Robaina Marcela Cristina, Amaral Nathalia, Bonecker Simone, Zalcberg Ilana Renault, Klumb Claudete Esteves
Abstract excerpt
We report an extremely rare case of a female child who presented the onset of primary myelofibrosis (PMF) harboring JAK2 (Janus Kinase 2 gene) mutation (JAK2V617F) when she was 15 months old. She was monitored over 25 years, a period in which she was treated with spleen radiotherapy and recombinant interferon α. She also underwent splenectomy when she was 13 years old, due to massive splenomegaly, anemia and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.